TORONTO, Aug. 14, 2014 /CNW/ - Alpha Laboratories is pleased to announce that the US Food and Drug Administration has completed a GMP inspection audit of its Pharmaceutical-Industrial Division without a single adverse finding. The very successful outcome is the latest installment in Alpha Laboratories' 43 years of proven commitment to highest quality standards. The routine GMP Inspection audit resulted in not one FDA-483 observation being issued.
The three day examination was performed by FDA staff at Alpha's Toronto, Ontario, Canada facility during the 3rd week of May, 2014. This is the second observation free result in the past 2 years.
Alpha Laboratories has successfully met the highest standard of GMP requirements of two different regulatory authorities this year, the FDA and Health Canada, as well as that of its many national and international clients.
"Our staff is dedicated to continuous enhancement of our quality systems as well as our levels of scientific expertise and experience" said Dr. Masood Bhatti, Chief Laboratory Operations for Alpha's Pharmaceutical/Industrial Division. "We are glad for this opportunity to provide an even stronger confirmation to our clientele for their confidence in us, which we very greatly value."
About Alpha Laboratories–Pharmaceutical Industrial Division: The founding division of Alpha Healthcare was established in 1971 and has grown into a premiere contract analytical testing organization supporting the pharmaceutical, nutraceutical, food and personal care industries. It offers complete GMP pharmaceutical support, including analytical chemistry, raw material testing, method development, microbiology, stability storage, product release testing, and regulatory affairs expertise.
SOURCE: Alpha Lab
For further information: Jill Fairbrother (416) 788-0539